StockNews.com Begins Coverage on Aeterna Zentaris (NASDAQ:AEZS)

StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZSGet Rating) (TSE:AEZ) in a research report issued on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their target price on shares of Aeterna Zentaris from $2.00 to $1.50 and set a “buy” rating for the company in a research report on Wednesday, March 30th.

AEZS opened at $0.31 on Wednesday. The firm has a market cap of $37.39 million, a P/E ratio of -4.40 and a beta of 1.61. Aeterna Zentaris has a 1-year low of $0.29 and a 1-year high of $1.16. The company has a 50 day simple moving average of $0.35 and a two-hundred day simple moving average of $0.42.

Aeterna Zentaris (NASDAQ:AEZSGet Rating) (TSE:AEZ) last posted its quarterly earnings results on Tuesday, March 29th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.02). Aeterna Zentaris had a negative net margin of 294.42% and a negative return on equity of 13.55%. Equities research analysts expect that Aeterna Zentaris will post -0.11 EPS for the current year.

Several large investors have recently modified their holdings of AEZS. Renaissance Technologies LLC boosted its position in shares of Aeterna Zentaris by 207.6% during the third quarter. Renaissance Technologies LLC now owns 341,400 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 230,400 shares during the last quarter. Natixis boosted its position in shares of Aeterna Zentaris by 31.7% during the third quarter. Natixis now owns 293,800 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 70,700 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Aeterna Zentaris by 72.3% during the third quarter. Geode Capital Management LLC now owns 91,492 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 38,395 shares during the last quarter. Finally, Virtu Financial LLC boosted its position in shares of Aeterna Zentaris by 37.0% during the fourth quarter. Virtu Financial LLC now owns 134,129 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 36,221 shares during the last quarter. Hedge funds and other institutional investors own 1.56% of the company’s stock.

Aeterna Zentaris Company Profile (Get Rating)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications.

Featured Stories

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.